Bernstein Liebhard LLP Agrees That Fosamax Warning Label Changes Are Needed
Bernstein Liebhard LLP concurs with FDA advisory panels’ recommendation to change labeling on bisphosphonates, such as Fosamax, in order to warn consumers of the increased risk of Fosamax femur fractures and other harmful side effects associated with long-term use. New York, NY (PRWEB) September 14, 2011 On September 8, 2011, two advisory panels to the U.S. Food and Drug Administration* (“FDA”) convened to discuss the safety of bisphosphonates such as Fosamax, which are used in the treatment of osteoporosis. Although the participants declined to make a recommendation as to whether the use
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Categories
- Articles 308
- Bankruptcy 44
- Business 133
- Cases & Codes 68
- Contracts 27
- Criminal Law 122
- Employment 24
- Expert Reports 3
- Expert Witness 34
- Family Law 57
- Form Letters 15
- Immigration 3
- Intellectual Prop 32
- Internet Law 10
- Law Practice 99
- Law School 2
- Legal Research 19
- Litigation 186
- Miscellaneous 64
- PR Web 41689
- Personal Injury 608
- Press Release 43
- Probate 54
- Real Estate 68
- Tax Law 23
- Workers Comp 4